Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Febuxostat × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Tumor Lysis Syndrome 2 Lymphoma 1 Leukemia 1 Inflammation 1 Hyperuricemia 1 Hematologic Neoplasms 1 Gout 1 Cardiovascular Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Arthritis 1

Interventions

Carboplatin 776 Pemetrexed 600 Cisplatin 542 Paclitaxel 489 pembrolizumab 459 Docetaxel 436 Gemcitabine 326 Erlotinib Hydrochloride 307 Radiotherapy 254 Nivolumab 240 Bevacizumab 232 osimertinib 177 Drug Therapy 160 durvalumab 155 atezolizumab 135 Gefitinib 134 Radiosurgery 129 Vinorelbine 111 Cetuximab 95 130-nm albumin-bound paclitaxel 93 Ipilimumab 84 Magnetic Resonance Spectroscopy 82 Taxes 78 Surgical Procedures, Operative 74 Afatinib 68 Albumin-Bound Paclitaxel 66 Etoposide 61 Specimen Handling 60 Cyclophosphamide 60 tislelizumab 58

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07485452 2026-03-20

OSIBBBOOST

Maastricht University Medical Center

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡